Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership
Illumina has launched a nonexclusive partnership with Emedgene, an artificial intelligence-based precision medicine company, to integrate automated interpretation of rare genetic disease data into Illumina’s TruSight™ Software Suite.
Through the collaboration, whose value has not been disclosed, TruSight will include Emedgene’s clinical rare disease application, one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases.
Illumina and Emedgene reason that through AI-enhanced interrogation of medical literature and phenotypes associated with rare disease, researchers will be better able to make new and unexpected discoveries based on rare disease data.
Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases
USA - English
News provided by
Share this article
Share this article
PALO ALTO, California, Dec. 16, 2020 /PRNewswire/ Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with
Illumina Inc. and the integration of automated interpretation into Illumina s TruSight™ Software Suite for rare genetic diseases. Emedgene s Clinical Rare Disease application is one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases.
Healthcare is in the midst of a leap towards precision medicine. Continued improvements in the cost of next-generation sequencing (NGS) technologies, such as those developed by Illumina, have dramatically accelerated the adoption of genetic testing. Consequently, data generated from genomics doubles every year and is expected to